| 1 | Fifty Years of Global Cardiovascular Research in Africa: A Scientometric Analysis, 1971 to 2021 | 4.0 | 16 | Citations (PDF) |
| 2 | Arterial hypertension – Clinical trials update 2021 | 3.2 | 84 | Citations (PDF) |
| 3 | Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial | 0.7 | 8 | Citations (PDF) |
| 4 | Sex Differences in Cardiovascular Research: A Scientometric Analysis | 4.0 | 8 | Citations (PDF) |
| 5 | Morphometric analysis of the human common hepatic artery reveals a rich and accessible target for sympathetic liver denervation | 3.4 | 9 | Citations (PDF) |
| 6 | Renal Denervation Prevents Atrial Arrhythmogenic Substrate Development in CKD | 13.1 | 25 | Citations (PDF) |
| 7 | Drug-coated balloons for small coronary artery disease in patients with chronic kidney disease: a pre-specified analysis of the BASKET-SMALL 2 trial | 2.8 | 18 | Citations (PDF) |
| 8 | Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia | 2.8 | 26 | Citations (PDF) |
| 9 | Clinical Trial Design Principles and Outcomes Definitions for Device-Based Therapies for Hypertension: A Consensus Document From the Hypertension Academic Research Consortium | 18.0 | 73 | Citations (PDF) |
| 10 | Photoinduced skin reactions of cardiovascular drugs—a systematic review | 4.0 | 18 | Citations (PDF) |
| 11 | Liver stiffness as surrogate parameter in emergency assessment for inpatient health care utilization | 2.3 | 2 | Citations (PDF) |
| 12 | Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial | 62.1 | 270 | Citations (PDF) |
| 13 | Effects of Medical Face Masks on Physical Performance in Patients With Coronary Artery Disease or Hypertension | 1.8 | 6 | Citations (PDF) |
| 14 | Drug-Coated Balloon for Small Coronary Artery Disease in Patients With and Without High-Bleeding Risk in the BASKET-SMALL 2 Trial | 4.8 | 65 | Citations (PDF) |
| 15 | Heart-Focused Anxiety, General Anxiety, Depression and Health-Related Quality of Life in Patients with Atrial Fibrillation Undergoing Pulmonary Vein Isolation | 2.5 | 16 | Citations (PDF) |
| 16 | Ischemic Stroke–A Scientometric Analysis | 2.3 | 6 | Citations (PDF) |
| 17 | Arterial hypertension - clinical trials update 2022 | 3.0 | 4 | Citations (PDF) |
| 18 | Twenty-Four-Hour Pulsatile Hemodynamics Predict Brachial Blood Pressure Response to Renal Denervation in the SPYRAL HTN-OFF MED Trial | 6.6 | 20 | Citations (PDF) |
| 19 | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012–2021 | 2.4 | 19 | Citations (PDF) |
| 20 | Cardio-renal interaction - Clinical trials update 2022 | 3.2 | 6 | Citations (PDF) |
| 21 | A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling | 4.9 | 15 | Citations (PDF) |
| 22 | Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age | 2.3 | 69 | Citations (PDF) |
| 23 | Inhibition of TRIF-Dependent Inflammation Decelerates Afterload-Induced Myocardial Remodeling | 3.4 | 1 | Citations (PDF) |
| 24 | Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European Association of Cardiovascular Imaging (EACVI), and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) | 4.0 | 45 | Citations (PDF) |
| 25 | Registration of Image Modalities for Analyses of Tissue Samples Using 3D Image Modelling | 2.2 | 4 | Citations (PDF) |
| 26 | Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine™ Infusion Catheter | 0.7 | 6 | Citations (PDF) |
| 27 | Myocardial infarction in a patient with single coronary artery - rare but real | 0.6 | 2 | Citations (PDF) |
| 28 | Remote Monitoring With Appropriate Reaction to Alerts Was Associated With Improved Outcomes in Chronic Heart Failure | 6.1 | 39 | Citations (PDF) |
| 29 | Valvular heart disease in patients with chronic kidney disease | 0.7 | 21 | Citations (PDF) |
| 30 | Renal outcomes and blood pressure patterns in diabetic and nondiabetic individuals at high cardiovascular risk | 2.1 | 11 | Citations (PDF) |
| 31 | One‐year results of the first‐in‐man study investigating the
Atrial Flow Regulator
for left atrial shunting in symptomatic heart failure patients: the
PRELIEVE
study | 7.3 | 68 | Citations (PDF) |
| 32 | The current status of renal denervation for the treatment of arterial hypertension | 5.6 | 18 | Citations (PDF) |
| 33 | Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry Analysis | 4.2 | 11 | Citations (PDF) |
| 34 | Kardiovaskuläre Forschung in Deutschland 2020 – eine szientometrische Analyse | 0.2 | 0 | Citations (PDF) |
| 35 | Inducibility of atrial fibrillation after catheter ablation predicts recurrences of atrial fibrillation: a meta‐analysis | 1.1 | 11 | Citations (PDF) |
| 36 | Arterielle Hypertonie – Was war 2020 wichtig? | 0.2 | 1 | Citations (PDF) |
| 37 | Device Therapy of Hypertension | 13.1 | 55 | Citations (PDF) |
| 38 | Renal denervation for the treatment of ventricular arrhythmias: A systematic review and meta‐analysis | 2.1 | 12 | Citations (PDF) |
| 39 | Predictors of blood pressure response to ultrasound renal denervation in the RADIANCE-HTN SOLO study | 2.5 | 34 | Citations (PDF) |
| 40 | Extra-Cardiac Targets in the Management of Cardiometabolic Disease: Device-Based Therapies | 3.1 | 4 | Citations (PDF) |
| 41 | Effects of face masks on performance and cardiorespiratory response in well-trained athletes | 2.8 | 29 | Citations (PDF) |
| 42 | Changes in Plasma Renin Activity After Renal Artery Sympathetic Denervation | 2.3 | 108 | Citations (PDF) |
| 43 | Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial) | 1.8 | 21 | Citations (PDF) |
| 44 | Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial | 62.1 | 395 | Citations (PDF) |
| 45 | European Society of Hypertension position paper on renal denervation 2021 | 2.1 | 124 | Citations (PDF) |
| 46 | Kriterien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK), der Deutschen Hochdruckliga e. V. DHL®/Deutschen Gesellschaft für Hypertonie und Prävention und der Deutschen Gesellschaft für Nephrologie (DGfN) zur Zertifizierung von „Renale-Denervations-Zentren (RDZ)“ – Update | 0.2 | 7 | Citations (PDF) |
| 47 | Mapping of an atrial tachycardia after Epicor™ high-intensity focused ultrasound ablation: A case report | 0.8 | 0 | Citations (PDF) |
| 48 | Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk | 34.5 | 510 | Citations (PDF) |
| 49 | Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial | 18.0 | 75 | Citations (PDF) |
| 50 | Effect of Heart Rate on the Outcome of Renal Denervation in Patients With Uncontrolled Hypertension | 2.3 | 54 | Citations (PDF) |
| 51 | A re-examination of the SPYRAL HTN-OFF MED Pivotal trial with respect to the underlying model assumptions | 1.2 | 7 | Citations (PDF) |
| 52 | Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications | 2.9 | 25 | Citations (PDF) |
| 53 | Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension | 4.8 | 15 | Citations (PDF) |
| 54 | Blood pressure lowering with alcohol‐mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location | 1.7 | 2 | Citations (PDF) |
| 55 | Hypertension trials update | 2.5 | 14 | Citations (PDF) |
| 56 | Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta‐analysis | 7.3 | 23 | Citations (PDF) |
| 57 | Evaluation and analytical applicability of a novel volumetric absorptive microsampling strategy for adherence monitoring of antihypertensive drugs by means of LC-HRMS/MS | 5.7 | 11 | Citations (PDF) |
| 58 | Update Hypertonie: Fokus auf die renale Denervation | 0.0 | 0 | Citations (PDF) |
| 59 | The Current Status of Devices for the Treatment of Resistant Hypertension | 2.0 | 11 | Citations (PDF) |
| 60 | Invasive left ventricle pressure–volume analysis: overview and practical clinical implications | 2.2 | 220 | Citations (PDF) |
| 61 | 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes | 2.2 | 6,243 | Citations (PDF) |
| 62 | Risk prediction with blood pressure during physical activity: A METter of exercise? | 2.0 | 1 | Citations (PDF) |
| 63 | Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial | 62.1 | 252 | Citations (PDF) |
| 64 | Randomized trials of invasive cardiovascular interventions that include a placebo control: a systematic review and meta-analysis | 2.2 | 21 | Citations (PDF) |
| 65 | Effects of edoxaban and warfarin on vascular remodeling: Atherosclerotic plaque progression and collateral artery growth | 2.5 | 12 | Citations (PDF) |
| 66 | A drug-induced hypotensive challenge to verify catheter-based radiofrequency renal denervation in an obese hypertensive swine model | 2.8 | 7 | Citations (PDF) |
| 67 | J-curve revisited | 2.2 | 0 | Citations (PDF) |
| 68 | Atrial fibrillation: selecting patients at risk for cardiovascular events by blood pressure | 2.2 | 1 | Citations (PDF) |
| 69 | Decline of emergency admissions for cardiovascular and cerebrovascular events after the outbreak of COVID-19 | 2.8 | 77 | Citations (PDF) |
| 70 | Research in Atrial Fibrillation | 3.4 | 11 | Citations (PDF) |
| 71 | Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany | 2.5 | 23 | Citations (PDF) |
| 72 | Development and implementation of blood pressure screening and referral guidelines for German community pharmacists | 2.0 | 6 | Citations (PDF) |
| 73 | Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions | 4.9 | 21 | Citations (PDF) |
| 74 | 12-Month Results From the Unblinded Phase of the RADIANCE-HTN SOLO Trial of Ultrasound Renal Denervation | 3.0 | 65 | Citations (PDF) |
| 75 | Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial | 2.2 | 33 | Citations (PDF) |
| 76 | Renal Denervation in High-Risk Patients With Hypertension | 2.3 | 114 | Citations (PDF) |
| 77 | Wissenschaftslandschaft Deutschland | 0.2 | 3 | Citations (PDF) |
| 78 | Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial | 62.1 | 557 | Citations (PDF) |
| 79 | Adherence to Antihypertensive Drugs Assessed by Hyphenated High‐Resolution Mass Spectrometry Analysis of Oral Fluids | 4.0 | 15 | Citations (PDF) |
| 80 | Off-the-shelf barrier for emergency intubation in the cardiac catheterization laboratory during the coronavirus disease 2019 (COVID-19) pandemic | 2.8 | 0 | Citations (PDF) |
| 81 | Changes in Stroke Volume After Renal Denervation | 6.6 | 16 | Citations (PDF) |
| 82 | Myocardial reperfusion reverses the J-curve association of cardiovascular risk and diastolic blood pressure in patients with left ventricular dysfunction and heart failure after myocardial infarction: insights from the EPHESUS trial | 2.2 | 57 | Citations (PDF) |
| 83 | Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension | 3.0 | 98 | Citations (PDF) |
| 84 | Rationale and design of two randomized sham-controlled trials of catheter-based renal denervation in subjects with uncontrolled hypertension in the absence (SPYRAL HTN-OFF MED Pivotal) and presence (SPYRAL HTN-ON MED Expansion) of antihypertensive medications: a novel approach using Bayesian design | 2.8 | 39 | Citations (PDF) |
| 85 | Survival After Coronary Revascularization With Paclitaxel-Coated Balloons | 2.3 | 110 | Citations (PDF) |
| 86 | Reduction of Outflow Tract Obstruction After PCI to Proximal LAD in a Patient With HOCM | 0.5 | 3 | Citations (PDF) |
| 87 | Proceedings from the 3rd European Clinical Consensus Conference for clinical trials in device-based hypertension therapies | 2.2 | 90 | Citations (PDF) |
| 88 | Catheter-based renal denervation as adjunct to pulmonary vein isolation for treatment of atrial fibrillation: a systematic review and meta-analysis | 2.1 | 29 | Citations (PDF) |
| 89 | Renal Denervation in Daily Practice: If So, How? | 2.3 | 2 | Citations (PDF) |
| 90 | Device-based therapies for arterial hypertension | 35.5 | 113 | Citations (PDF) |
| 91 | Effect of renal denervation in attenuating the stress of morning surge in blood pressure: post-hoc analysis from the SPYRAL HTN-ON MED trial | 2.8 | 29 | Citations (PDF) |
| 92 | Where is renal nerve ablation going? | 2.2 | 2 | Citations (PDF) |
| 93 | Confounding Factors in Renal Denervation Trials | 6.6 | 45 | Citations (PDF) |
| 94 | ESC Council on hypertension position document on the management of hypertensive emergencies | 4.0 | 238 | Citations (PDF) |
| 95 | Procedural and Anatomical Determinants of Multielectrode Renal Denervation Efficacy | 6.6 | 24 | Citations (PDF) |
| 96 | Changes in 24-Hour Patterns of Blood Pressure in Hypertension Following Renal Denervation Therapy | 6.6 | 25 | Citations (PDF) |
| 97 | Renal Denervation for Treating Hypertension | 3.0 | 83 | Citations (PDF) |
| 98 | Renal Denervation: Is It Ready for Prime Time? | 2.9 | 11 | Citations (PDF) |
| 99 | Looking back and thinking forwards — 15 years of cardiology and cardiovascular research | 35.5 | 17 | Citations (PDF) |
| 100 | Renal Denervation Update From the International Sympathetic Nervous System Summit | 2.3 | 100 | Citations (PDF) |
| 101 | Arteriovenous Fistula, Blood Pressure, and Shunt Flow: A Thin Line That Separates Beneficial From Detrimental Effects | 2.0 | 0 | Citations (PDF) |
| 102 | Development and application of a LC-HRMS/MS method for analyzing antihypertensive drugs in oral fluid for monitoring drug adherence | 5.7 | 24 | Citations (PDF) |
| 103 | Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial | 18.0 | 117 | Citations (PDF) |
| 104 | Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry | 2.2 | 278 | Citations (PDF) |
| 105 | Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk | 2.2 | 65 | Citations (PDF) |
| 106 | Effects of Arteriovenous Fistula on Blood Pressure in Patients With End‐Stage Renal Disease: A Systematic Meta‐Analysis | 4.0 | 42 | Citations (PDF) |
| 107 | Safety and efficacy of endovascular ultrasound renal denervation in resistant hypertension | 2.1 | 21 | Citations (PDF) |
| 108 | Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study | 2.9 | 61 | Citations (PDF) |
| 109 | Ambulatory heart rate reduction after catheter-based renal denervation in hypertensive patients not receiving anti-hypertensive medications: data from SPYRAL HTN-OFF MED, a randomized, sham-controlled, proof-of-concept trial | 2.2 | 83 | Citations (PDF) |
| 110 | Effects of renal denervation on 24-h heart rate and heart rate variability in resistant hypertension | 2.8 | 13 | Citations (PDF) |
| 111 | Contemporary scientometric analyses using a novel web application: the science performance evaluation (SciPE) approach | 2.8 | 17 | Citations (PDF) |
| 112 | One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry | 2.8 | 33 | Citations (PDF) |
| 113 | Renal denervation: dark past, bright future? | 0.5 | 4 | Citations (PDF) |
| 114 | Anatomical and procedural determinants of ambulatory blood pressure lowering following catheter-based renal denervation using radiofrequency | 0.7 | 14 | Citations (PDF) |
| 115 | Real-time left ventricular pressure–volume loops during percutaneous central arteriovenous anastomosis | 2.2 | 8 | Citations (PDF) |
| 116 | Modulation of renal sympathetic innervation: recent insights beyond blood pressure control | 1.9 | 26 | Citations (PDF) |
| 117 | The association between different features of sleep‐disordered breathing and blood pressure: A cross‐sectional study | 2.0 | 23 | Citations (PDF) |
| 118 | Renal sympathetic denervation restores aortic distensibility in patients with resistant hypertension: data from a multi-center trial | 2.8 | 22 | Citations (PDF) |
| 119 | A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: The RADIANCE-HTN and REQUIRE clinical study designs | 2.9 | 75 | Citations (PDF) |
| 120 | Procedural and anatomical predictors of renal denervation efficacy using two radiofrequency renal denervation catheters in a porcine model | 2.1 | 15 | Citations (PDF) |
| 121 | 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension | 1.7 | 719 | Citations (PDF) |
| 122 | Twenty-Four–Hour Ambulatory Blood Pressure Reduction Patterns After Renal Denervation in the SPYRAL HTN-OFF MED Trial | 18.0 | 52 | Citations (PDF) |
| 123 | Catheter-based renal denervation: the next chapter begins | 2.2 | 21 | Citations (PDF) |
| 124 | European Society of Hypertension position paper on renal denervation 2018 | 2.1 | 44 | Citations (PDF) |
| 125 | Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial | 62.1 | 750 | Citations (PDF) |
| 126 | Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial | 62.1 | 698 | Citations (PDF) |
| 127 | 2018 ESC/ESH Guidelines for the management of arterial hypertension | 2.2 | 8,913 | Citations (PDF) |
| 128 | Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial | 62.1 | 434 | Citations (PDF) |
| 129 | Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120–140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials | 2.2 | 120 | Citations (PDF) |
| 130 | Secondary rise in blood pressure and leg swelling after central arteriovenous anastomosis | 2.8 | 4 | Citations (PDF) |
| 131 | Will ORBITA change my practice? ORBITA trial: Objective Randomised Blinded Investigation with optimal medical Therapy of Angioplasty in stable angina | 3.0 | 1 | Citations (PDF) |
| 132 | Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry | 2.2 | 109 | Citations (PDF) |
| 133 | Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction | 2.0 | 47 | Citations (PDF) |
| 134 | Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model | 2.2 | 25 | Citations (PDF) |
| 135 | Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future | 2.2 | 112 | Citations (PDF) |
| 136 | Improvement in health‐related quality of life after renal sympathetic denervation in real‐world hypertensive patients: 12‐month outcomes in the Global SYMPLICITY Registry | 2.0 | 15 | Citations (PDF) |
| 137 | Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials | 62.1 | 306 | Citations (PDF) |
| 138 | Blood Pressure Response to Main Renal Artery and Combined Main Renal Artery Plus Branch Renal Denervation in Patients With Resistant Hypertension | 4.0 | 69 | Citations (PDF) |
| 139 | Comparison of branch and distally focused main renal artery denervation using two different radio-frequency systems in a porcine model | 2.2 | 3 | Citations (PDF) |
| 140 | Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial | 62.1 | 715 | Citations (PDF) |
| 141 | Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension? | 1.9 | 7 | Citations (PDF) |
| 142 | Renal denervation for treatment of hypertension – will 2017 be the year of enlightenment? | 3.0 | 0 | Citations (PDF) |
| 143 | Non-Adherence to Ivabradine and Placebo and Outcomes in Chronic Heart Failure: An Analysis from SHIFT | 7.3 | 23 | Citations (PDF) |
| 144 | Device-based Therapy for Hypertension | 4.7 | 42 | Citations (PDF) |
| 145 | Effect of Arteriovenous Anastomosis on Blood Pressure Reduction in Patients With Isolated Systolic Hypertension Compared With Combined Hypertension | 4.0 | 22 | Citations (PDF) |
| 146 | Impact of obstructive and central apneas on ventricular repolarisation: lessons learned from studies in man and pigs | 2.8 | 25 | Citations (PDF) |
| 147 | Renal denervation for treatment of ventricular arrhythmias: data from an International Multicenter Registry | 2.8 | 72 | Citations (PDF) |
| 148 | Catheter-based radio-frequency renal nerve denervation lowers blood pressure in obese hypertensive swine model | 2.1 | 22 | Citations (PDF) |
| 149 | Modulation of the sympathetic nervous system by renal denervation prevents reduction of aortic distensibility in atherosclerosis prone ApoE-deficient rats | 6.4 | 12 | Citations (PDF) |
| 150 | The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications | 2.9 | 154 | Citations (PDF) |
| 151 | Impact of Lesion Placement on Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation | 2.3 | 194 | Citations (PDF) |
| 152 | Blood pressure changes after catheter-based renal denervation are related to reductions in total peripheral resistance | 2.1 | 42 | Citations (PDF) |
| 153 | Renal denervation preserves renal function in patients with chronic kidney disease and resistant hypertension | 2.1 | 119 | Citations (PDF) |
| 154 | Impact of number of prescribed medications on visit-to-visit variability of blood pressure | 2.1 | 5 | Citations (PDF) |
| 155 | Atrial Remodeling Following Catheter-Based Renal Denervation Occurs in a Blood Pressure– and Heart Rate–Independent Manner | 3.0 | 41 | Citations (PDF) |
| 156 | Drug Therapy for the Patient With Resistant Hypertension | 1.0 | 1 | Citations (PDF) |
| 157 | Obstructive respiratory events and premature atrial contractions after cardioversion | 8.7 | 43 | Citations (PDF) |
| 158 | Progression of Kidney Injury and Cardiac Remodeling in Obese Spontaneously Hypertensive Rats: The Role of Renal Sympathetic Innervation | 2.0 | 58 | Citations (PDF) |
| 159 | First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension | 6.6 | 188 | Citations (PDF) |
| 160 | 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias | 3.0 | 85 | Citations (PDF) |
| 161 | Chronische Herzinsuffizienz | 0.4 | 3 | Citations (PDF) |
| 162 | Arterial microanatomy determines the success of energy-based renal denervation in controlling hypertension | 12.5 | 67 | Citations (PDF) |
| 163 | Catheter-Based Renal Denervation Reduces Atrial Nerve Sprouting and Complexity of Atrial Fibrillation in Goats | 6.1 | 67 | Citations (PDF) |
| 164 | Hochdrucktherapie 2015 | 0.2 | 5 | Citations (PDF) |
| 165 | Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis | 2.8 | 81 | Citations (PDF) |
| 166 | Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design: Figure 1 | 2.2 | 182 | Citations (PDF) |
| 167 | Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension | 6.6 | 116 | Citations (PDF) |
| 168 | Renal denervation: symply trapped by complexity? | 2.2 | 69 | Citations (PDF) |
| 169 | Renal nerve ablationHeart, 2015, 101, 320-328 | 3.9 | 5 | Citations (PDF) |
| 170 | Witnessed drug intake before planned denervation—Always harmless? | 2.2 | 9 | Citations (PDF) |
| 171 | Effects of catheter-based renal denervation on cardiac sympathetic activity and innervation in patients with resistant hypertension | 2.8 | 59 | Citations (PDF) |
| 172 | Renal denervation reloaded: where to go from here? | 3.0 | 3 | Citations (PDF) |
| 173 | Catheter-based Renal Denervation for Therapy of Hypertension: Is There a Hope for Its Resurgence? | 0.1 | 0 | Citations (PDF) |
| 174 | Effects of Renal Denervation On Atrial Arrhythmogenesis | 1.0 | 5 | Citations (PDF) |
| 175 | Efficacy and Safety of Catheter-Based Radiofrequency Renal Denervation in Stented Renal Arteries | 4.8 | 21 | Citations (PDF) |
| 176 | Response to Letter Regarding Article, “Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond?” | 13.1 | 0 | Citations (PDF) |
| 177 | Effect of renal denervation on left ventricular mass and function in patients with resistant hypertension: data from a multi-centre cardiovascular magnetic resonance imaging trial | 2.2 | 161 | Citations (PDF) |
| 178 | Effect of Obstructive Respiratory Events on Blood Pressure and Renal Perfusion in a Pig Model for Sleep Apnea | 2.0 | 42 | Citations (PDF) |
| 179 | Renal nerve ablation after SYMPLICITY HTN-3: confused at the higher level? | 2.2 | 70 | Citations (PDF) |
| 180 | Improvement of albuminuria after renal denervation | 2.2 | 76 | Citations (PDF) |
| 181 | Renal Denervation: A Novel Non-pharmacological Approach in Heart Failure | 2.0 | 6 | Citations (PDF) |
| 182 | Improvements in Left Ventricular Hypertrophy and Diastolic Function Following Renal Denervation | 2.3 | 113 | Citations (PDF) |
| 183 | Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study | 62.1 | 598 | Citations (PDF) |
| 184 | Atrial Autonomic Innervation | 2.3 | 146 | Citations (PDF) |
| 185 | Renal Denervation for the Treatment of Cardiovascular High Risk-Hypertension or Beyond? | 13.1 | 80 | Citations (PDF) |
| 186 | Welche kardiale Diagnostik braucht Ihr Hypertoniker? | 0.0 | 0 | Citations (PDF) |
| 187 | Effects of Renal Sympathetic Denervation on Exercise Blood Pressure, Heart Rate, and Capacity in Patients With Resistant Hypertension | 6.6 | 24 | Citations (PDF) |
| 188 | Interventionelle Hypertonietherapie bei Diabetes mellitus | 0.7 | 0 | Citations (PDF) |
| 189 | Renal denervation: effects on atrial electrophysiology and arrhythmias | 2.8 | 40 | Citations (PDF) |
| 190 | Novel and Nonpharmacologic Approaches to Cardio-Protection in Hypertension | 4.7 | 6 | Citations (PDF) |
| 191 | Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial | 2.2 | 254 | Citations (PDF) |
| 192 | Innervation Patterns May Limit Response to Endovascular Renal Denervation | 2.3 | 121 | Citations (PDF) |
| 193 | What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension | 3.0 | 48 | Citations (PDF) |
| 194 | Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs | 2.7 | 137 | Citations (PDF) |
| 195 | Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension | 2.2 | 122 | Citations (PDF) |
| 196 | Effect of Renal Denervation on Neurohumoral Activation Triggering Atrial Fibrillation in Obstructive Sleep Apnea | 6.6 | 135 | Citations (PDF) |
| 197 | Renal Sympathetic Denervation Provides Ventricular Rate Control But Does Not Prevent Atrial Electrical Remodeling During Atrial Fibrillation | 6.6 | 109 | Citations (PDF) |
| 198 | Catheter-Based Renal Nerve Ablation and Centrally Generated Sympathetic Activity in Difficult-to-Control Hypertensive Patients: Prospective Case Series | 6.6 | 8 | Citations (PDF) |
| 199 | Feasibility of catheter-based renal nerve ablation and effects on sympathetic nerve activity and blood pressure in patients with end-stage renal disease | 2.2 | 135 | Citations (PDF) |
| 200 | Renal sympathetic denervation: applications in hypertension and beyond | 35.5 | 78 | Citations (PDF) |
| 201 | Renal Denervation in the Treatment of Hypertension | 4.7 | 5 | Citations (PDF) |
| 202 | Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension | 18.0 | 242 | Citations (PDF) |
| 203 | Percutaneous renal denervation: new treatment option for resistant hypertension and more?Heart, 2013, 99, 1129-1134 | 3.9 | 15 | Citations (PDF) |
| 204 | Interpreting treatment-induced blood pressure reductions measured by ambulatory blood pressure monitoring | 2.5 | 19 | Citations (PDF) |
| 205 | Treating resistant hypertension: role of renal denervation | 3.3 | 12 | Citations (PDF) |
| 206 | Association of vitamin D status and blood pressure response after renal denervation | 2.8 | 22 | Citations (PDF) |
| 207 | The biophysics of renal sympathetic denervation using radiofrequency energy | 2.8 | 37 | Citations (PDF) |
| 208 | Catheter-based Renal Sympathetic Denervation – Long-term Symplicity™ Renal Denervation Clinical Evidence, New Data and Future Perspectives | 1.4 | 8 | Citations (PDF) |
| 209 | Application in Hypertension of Renal Sympathetic Denervation – A Review | 1.4 | 1 | Citations (PDF) |
| 210 | Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation | 3.0 | 30 | Citations (PDF) |
| 211 | Renal denervation: expanding the indication | 3.0 | 7 | Citations (PDF) |
| 212 | Potential role of renal sympathetic denervation for the treatment of cardiac arrhythmias | 3.0 | 22 | Citations (PDF) |
| 213 | Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure | 3.0 | 12 | Citations (PDF) |
| 214 | Renal Denervation in Moderate to Severe CKD | 0.4 | 345 | Citations (PDF) |
| 215 | Renal Sympathetic Denervation Suppresses Postapneic Blood Pressure Rises and Atrial Fibrillation in a Model for Sleep Apnea | 6.6 | 223 | Citations (PDF) |
| 216 | 311 FEASIBILITY OF CATHETER-BASED RENAL DENERVATION AND EFFECTS ON SYMPATHETIC NERVE ACTIVITY AND BLOOD PRESSURE IN PATIENTS WITH END-STAGE RENAL DISEASE | 2.1 | 1 | Citations (PDF) |
| 217 | Effects of Renal Sympathetic Denervation on Arterial Stiffness and Central Hemodynamics in Patients With Resistant Hypertension | 2.3 | 150 | Citations (PDF) |
| 218 | Renal Sympathetic Denervation Reduces Left Ventricular Hypertrophy and Improves Cardiac Function in Patients With Resistant Hypertension | 2.3 | 487 | Citations (PDF) |
| 219 | Cardiac remodeling and myocardial dysfunction in obese spontaneously hypertensive rats | 6.4 | 23 | Citations (PDF) |
| 220 | Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension | 6.6 | 300 | Citations (PDF) |
| 221 | Inadequate Reporting of Concomitant Drug Treatment in Cardiovascular Interventional Head‐to‐Head Trials | 2.0 | 7 | Citations (PDF) |
| 222 | Recent advances in the treatment of hypertension | 1.8 | 15 | Citations (PDF) |
| 223 | Variability of ventricular repolarization during hypoglycemia | 2.2 | 1 | Citations (PDF) |
| 224 | Sympatho-renal axis in chronic disease | 2.8 | 161 | Citations (PDF) |
| 225 | Renale Sympathikusdenervation | 0.7 | 5 | Citations (PDF) |
| 226 | Device-Based Antihypertensive Therapy | 18.0 | 145 | Citations (PDF) |
| 227 | Renal sympathetic denervation for treatment of electrical storm: first-in-man experience | 2.8 | 220 | Citations (PDF) |
| 228 | The cardiopulmonary continuum systemic inflammation as ‘common soil’ of heart and lung disease | 2.2 | 71 | Citations (PDF) |
| 229 | In Reply | 0.1 | 0 | Citations (PDF) |
| 230 | “Dear Doctor” Warning Letter (Rote-Hand-Brief) on Hydrochlorothiazide and Its Impact on Antihypertensive Prescription | 0.1 | 3 | Citations (PDF) |
| 231 | Effect of Bisoprolol Versus Other Beta-Blockers on Glycemic Control and Metabolic Parameters in Type 2 Diabetes: A Retrospective Cohort Study | 2.1 | 3 | Citations (PDF) |
| 232 | Decoding Fibroblast Diversity Associated with the Postnatal Loss of Cardiac Regenerative Capacity | 4.4 | 0 | Citations (PDF) |
| 233 | 26-A-15422-ACC REDUCING HYPERTENSIVE URGENCY WITH RADIOFREQUENCY RENAL DENERVATION THROUGH THREE YEARS: INSIGHTS FROM THE SPYRAL HTN-ON AND OFF MED TRIALS | 2.3 | 0 | Citations (PDF) |
